Correlation Between Eupraxia Pharmaceuticals and OnKure Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and OnKure Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and OnKure Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eupraxia Pharmaceuticals Common and OnKure Therapeutics,, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and OnKure Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of OnKure Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and OnKure Therapeutics,.

Diversification Opportunities for Eupraxia Pharmaceuticals and OnKure Therapeutics,

-0.59

Correlation Coefficient

Eupraxia Pharmaceuticals  OnKure Therapeutics,

Excellent diversification

The 3 months correlation between Eupraxia and OnKure is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals Commo and OnKure Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OnKure Therapeutics, and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals Common are associated (or correlated) with OnKure Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OnKure Therapeutics, has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and OnKure Therapeutics, go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and OnKure Therapeutics,

Given the investment horizon of 90 days Eupraxia Pharmaceuticals Common is expected to generate 1.0 times more return on investment than OnKure Therapeutics,. However, Eupraxia Pharmaceuticals Common is 1.0 times less risky than OnKure Therapeutics,. It trades about -0.13 of its potential returns per unit of risk. OnKure Therapeutics, is currently generating about -0.57 per unit of risk. If you would invest  349.00  in Eupraxia Pharmaceuticals Common on September 23, 2024 and sell it today you would lose (50.00) from holding Eupraxia Pharmaceuticals Common or give up 14.33% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Eupraxia Pharmaceuticals Commo  vs.  OnKure Therapeutics,

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

OnKure Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days OnKure Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with fragile performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Eupraxia Pharmaceuticals and OnKure Therapeutics,

The main advantage of trading using opposite Eupraxia Pharmaceuticals and OnKure Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, OnKure Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OnKure Therapeutics, will offset losses from the drop in OnKure Therapeutics,'s long position.

The idea behind Eupraxia Pharmaceuticals Common and OnKure Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.